Adherence to the MeDi diet may reduce the risk of MCI and AD. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Research
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
The Mediterranean diet (MD) has shown to reduce the occurrence of several chronic diseases. 4 key findings →
Design: cohort study Participants: 16,160 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Multidomain lifestyle interventions represents a promising strategy to counteract cognitive decline in older age. 2 key findings →
Participants: 25 Evidence: high
Full summary, score breakdown and related studies → Original source
A 2-year lifestyle intervention was able to maintain the daily functioning of the at-risk older population. 3 key findings →
Design: randomized controlled trial Participants: 1,260 Evidence: high
Full summary, score breakdown and related studies → Original source
76/100
Cognitive impairment is a central non-motor symptom of Parkinson's disease (PD), and there are no established treatments. 4 key findings →
Design: meta-analysis Participants: 679 Evidence: high
Full summary, score breakdown and related studies → Original source
Cognitive training interventions show to be a potential treatment to ameliorate depression in people with cognitive impairment. 5 key findings →
Participants: 2,551 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of 6321 participants (mean [SE] age, 56.1 [0.18] years at visit 1; n = 4077 women [57.8%]) were included. 3 key findings →
Design: cohort study Participants: 4,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Aging is characterized by cognitive decline affecting daily functioning. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Combined multi-domain interventions may contribute to preventing or delaying disease progression. 1 key finding →
Design: randomized controlled trial Participants: 33 Evidence: high
Full summary, score breakdown and related studies → Original source
76/100
Cohort studies suggest that the Mediterranean diet is associated with better global cognition in older adults, slower cognitive decline and lower risk of dementia. 5 key findings →
Design: cohort study Participants: 249,511 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The 2-year multidomain FINGER intervention may modulate white matter microstructural alterations. 2 key findings →
Design: randomized controlled trial Participants: 34 Evidence: high
Full summary, score breakdown and related studies → Original source
There is emerging evidence linking fruit and vegetable consumption and cognitive function. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
76/100
Systematic cognitive training had no effect on global cognition or HRQoL in community-living persons with mild to moderate dementia. 1 key finding →
Design: randomized controlled trial Participants: 147 Evidence: high
Full summary, score breakdown and related studies → Original source
Aerobic exercise in early AD is associated with benefits in functional ability. 4 key findings →
Design: randomized controlled trial Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source
Question Does physical exercise training improve physical function and quality of life in people with cognitive impairment and dementia? 4 key findings →
Design: systematic review Participants: 3,988 Evidence: high
Full summary, score breakdown and related studies → Original source
Study staff and participants will be kept blind until recruitment is complete for each group. 5 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source
Exercise training for patients with Alzheimer disease combined with teaching caregivers how to manage behavioral problems may help decrease the frailty and behavioral impairment that are often prevalent in patients with Alzheimer disease. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These results suggest that regular exercise is associated with a delay in onset of dementia and Alzheimer disease, further supporting its value for elderly persons. 5 key findings →
Design: cohort study Participants: 1,740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
75/100
There is moderate-to-strong support that PA benefits cognitive functioning during early and late periods of the life span and in certain populations characterized by cognitive deficits. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Adherence to a Mediterranean diet may contribute to the prevention of a series of brain diseases; this may be of special value given the aging of Western societies. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Main results Seventeen trials with 1067 participants met the inclusion criteria. 5 key findings →
Design: meta-analysis Participants: 1,067 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
RO emphasised the engagement of nursing assistants in a hopeful, therapeutic process but became associated with a rigid, confrontational approach to people with dementia, leading to its use becoming less and less common. 3 key findings →
Design: systematic review Participants: 718 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We found that multiple sleep measures predicted future risk of stroke and dementia, but these associations were attenuated after controlling for cardiovascular risk factors and were absent in MR analyses for Alzheimer disease. 4 key findings →
Design: cross-sectional Participants: 502,383 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The SYNERGIC Trial will establish the efficacy and feasibility of a multimodal intervention to improve cognitive performance and mobility outcomes in MCI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Baseline sleep disturbance was associated with a faster rate of longitudinal CSF Aβ42 decline. 4 key findings →
Design: longitudinal study Participants: 1,205 Evidence: moderate
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,888 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study
- Contribution of socioeconomic, lifestyle, and medical risk factors to disparities in dementia and mortality
- The Mediterranean diet and health: a comprehensive overview
- Loneliness, cerebrovascular and Alzheimer's disease pathology, and cognition
- The MIND diet association with lower microglial inflammation in the hippocampus: A Community‐Based Neuropathologic Study
- Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank
- The Dialogue Between Neuroinflammation and Adult Neurogenesis: Mechanisms Involved and Alterations in Neurological Diseases
- A practical algorithm for managing Alzheimer's disease: what, when, and why?
- Prevention of Alzheimer's disease through diet: An exploratory review
- Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →